You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中国生物制药(01177.HK)旗下抗菌药"利奈唑胺葡萄糖注射液"获通过一致性评价
格隆汇 06-02 21:30

格隆汇6月2日丨中国生物制药(01177.HK)宣布,集团研制的抗菌药"利奈唑胺葡萄糖注射液"(商品名:天礼)已获中华人民共和国国家药品监督管理局颁发药品补充申请批准通知书,通过了仿制药质量和疗效一致性评价。利奈唑胺用于治疗由特定微生物敏感株引起的下列感染:院内获得性肺炎,社区获得性肺炎,复杂性皮肤和皮肤软组织感染,非复杂性皮肤和皮肤软组织感染,万古霉素耐药的屎肠球菌感染。

利奈唑胺属于恶唑烷酮类抗菌药物。其作用机制独特,对多种临床致病的革兰氏阳性(G+)菌有效,具有抗菌谱广、体液和组织穿透性强、安全性高等特点,与其他抗菌药物(如头孢菌素类、喹诺酮类或β内醯胺类抗生素)间几乎没有交叉耐药性,在呼吸、血液、重症加强护理病房(ICU)、结核╱传染等科室广泛使用。

易瑞达(集团另一个早前获通过一致性评价的利奈唑胺产品)和天礼相继过评,这将有助于集团利奈唑胺产品的进一步市场拓展。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account